Ginkgo Bioworks Holdings, Inc.
DNA
$6.82
$0.131.94%
NYSE
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -14.01% | -21.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -14.01% | -21.71% | |||
| Cost of Revenue | -42.97% | -13.63% | |||
| Gross Profit | 0.23% | -25.15% | |||
| SG&A Expenses | 2.36% | 3.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -18.62% | 14.03% | |||
| Operating Income | 20.65% | -42.68% | |||
| Income Before Tax | -0.79% | -33.29% | |||
| Income Tax Expenses | -64,400.00% | 100.35% | |||
| Earnings from Continuing Operations | 0.00% | -33.92% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | -33.92% | |||
| EBIT | 20.65% | -42.68% | |||
| EBITDA | 30.67% | -91.22% | |||
| EPS Basic | 2.54% | -32.05% | |||
| Normalized Basic EPS | 26.91% | -43.87% | |||
| EPS Diluted | 2.22% | -31.95% | |||
| Normalized Diluted EPS | 26.91% | -43.87% | |||
| Average Basic Shares Outstanding | 2.60% | 1.41% | |||
| Average Diluted Shares Outstanding | 2.60% | 1.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||